Author argues Revolution Medicines' next-generation oncology asset and takeover interest make the stock a strong buy.
RVMD — LONG The author claims RVMD owns a next-generation oncology asset with successor trials already running, and Merck has a $30B/year asset in Keytruda to protect. Stifel wrote that a proposed $28-30 takeover price for RVMD may not be enough. The author believes whoever acquires the asset will own the market and advises buying shares aggressively.
RVMD owns the next gen asset in oncology and already has trials running on its successor which is even better.